Search - tctmd.com

Displaying 161 - 180 of 233

Sort: Relevancy | Date

News Conference News CRT 2024

Full AGENT IDE Results Affirm Benefits of DCB for In-Stent Restenosis

L.A. McKeown

March 09, 2024

News Daily News

Patients With CKD Remain Underrepresented in Trials of CV Meds

Todd Neale

March 08, 2024

News Conference News THT 2024

Small Study Hints at Apixaban’s Potential in LVAD-Treated Patients

Michael O'Riordan

March 07, 2024

News Conference News THT 2024

Durable 1-Year Outcomes With Coronary Sinus Shunt for HF: ALT-FLOW EFS

Michael O'Riordan

March 06, 2024

Presentation THT 2024

Cardiac Contractility Modulator as an Option for Advanced Heart Failure Patients Dependent on Low Dose inotropes

Presenter: Kanika P. Mody

March 06, 2024

Presentation THT 2024

Derivation and Validation of a Multicenter Model to Identify Candidates for Advanced HF Therapies with High Potential to Achieve post-LVAD Reverse Cardiac Remodeling

Presenter: Stavros G. Drakos

March 05, 2024

Presentation THT Abstracts 2024

Use of EMR-Based Clinical Workflows Improves Access and Equity for Patients with Advanced Heart Failure 2013 A Single Center Experience

March 05, 2024

Presentation THT 2024

How to Manage VT in Advanced HF and Post-LVAD Patients

Presenter: Jakub Sroubek

March 05, 2024

Presentation THT 2024

Patient Identification and Post-implant Management within an Advanced Heart Failure Program

Presenter: Dmitry Yaranov

March 05, 2024

Presentation THT 2024

A Phase 1 Clinical Gene Therapy Trial in Patients With Advanced Heart Failure Using a Rationally Designed Cardiotropic AAV Vector Targeting Protein Phosphatase Inhibitor-1

Presenter: Lothar Roessig

March 05, 2024

Presentation THT 2024

Alternative Advanced Therapy: Case of Cardiac Contractility Modulation in Stage D Ischemic Cardiomyopathy

Presenter: Daniel Asemota

March 05, 2024

Presentation THT Abstracts 2024

Advanced Therapy Eligibility in Patients with Axillary Impella for Cardiogenic Shock

Presenter: McKenzie Sicke

March 04, 2024

Presentation THT Abstracts 2024

Aortic Pulsatility Index does not predict use of temporary mechanical support among patients with Advanced Heart Failure Awaiting Cardiac Transplant.

Presenter: Muhammad Saad

March 04, 2024

Presentation THT Abstracts 2024

Utilization of Advanced Heart Failure Interventions Observed in the Baroreflex Activation Therapy for Heart Failure (BeAT-HF) Trial

Presenter: William Abraham

March 04, 2024

Presentation THT 2024

Advances in Hemocompatibility

Presenter: Mandeep R. Mehra

March 04, 2024

Presentation THT 2024

Durrable LVADs: Innovations in Programming and Management Required to Advance the Field

Presenter: Melana Yuzefpolskaya

March 04, 2024

Presentation THT 2024

Durable LVADs: Pump Innovations Required to Advance the Field

Presenter: Francis D. Pagani

March 04, 2024

Presentation THT 2024

Utilization of Advanced Heart Failure Interventions Observed in the Baroreflex Activation Therapy for Heart Failure (BeAT-HF) Trial

Presenter: William T. Abraham

March 04, 2024

News Daily News

Infective Endocarditis in Opioid Users: Care Must Go Beyond the Heart

Caitlin E. Cox

February 26, 2024

News Featured Fellow

Mohammed “Hamdy” Abozenah, MD

Yael L. Maxwell

February 23, 2024

Advertisement

Full AGENT IDE Results Affirm Benefits of DCB for In-Stent Restenosis

Patients With CKD Remain Underrepresented in Trials of CV Meds

Small Study Hints at Apixaban’s Potential in LVAD-Treated Patients

Durable 1-Year Outcomes With Coronary Sinus Shunt for HF: ALT-FLOW EFS

Cardiac Contractility Modulator as an Option for Advanced Heart Failure Patients Dependent on Low Dose inotropes

Derivation and Validation of a Multicenter Model to Identify Candidates for Advanced HF Therapies with High Potential to Achieve post-LVAD Reverse Cardiac Remodeling

Use of EMR-Based Clinical Workflows Improves Access and Equity for Patients with Advanced Heart Failure 2013 A Single Center Experience

How to Manage VT in Advanced HF and Post-LVAD Patients

Patient Identification and Post-implant Management within an Advanced Heart Failure Program

A Phase 1 Clinical Gene Therapy Trial in Patients With Advanced Heart Failure Using a Rationally Designed Cardiotropic AAV Vector Targeting Protein Phosphatase Inhibitor-1

Alternative Advanced Therapy: Case of Cardiac Contractility Modulation in Stage D Ischemic Cardiomyopathy

Advanced Therapy Eligibility in Patients with Axillary Impella for Cardiogenic Shock

Aortic Pulsatility Index does not predict use of temporary mechanical support among patients with Advanced Heart Failure Awaiting Cardiac Transplant.

Utilization of Advanced Heart Failure Interventions Observed in the Baroreflex Activation Therapy for Heart Failure (BeAT-HF) Trial

Advances in Hemocompatibility

Durrable LVADs: Innovations in Programming and Management Required to Advance the Field

Durable LVADs: Pump Innovations Required to Advance the Field

Utilization of Advanced Heart Failure Interventions Observed in the Baroreflex Activation Therapy for Heart Failure (BeAT-HF) Trial

Infective Endocarditis in Opioid Users: Care Must Go Beyond the Heart

Mohammed “Hamdy” Abozenah, MD

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content